Onxeo Highlights First Outcomes of Livatag Preclinical Plan
Onxeo S.A. released data from two in vivo studies of the Livatag preclinical plan confirming that the nanoparticle formulation meets the pharmacological requirements for a hepatocellular carcinoma (HCC) treatment and, furthermore, that the combination of Livatag with immunotherapy produces an enhanced efficacy effect, validating Onxeo's strategy to explore further potential indications for its key product candidate.
According to a release, the studies were performed in an orthotopic (implantation of tumor cells into the liver of mice) HCC model in immune-competent mice. Orthotopic models are considered relevant to the clinical situation and a good predictor of drug efficacy. Results demonstrate that Livatag (doxorubicin Transdrug) generates a 12-fold increase in exposure in the tumor tissue within the liver compared to free doxorubicin, without increasing the drug's exposure in the heart or other vital organs. These findings complete, and go beyond, data from a mechanistic study of Livatag previously reported at the 2016 American Association for Cancer Research (AACR) Annual Meeting that revealed that the distribution of Livatag nanoparticles in healthy liver was approximately six times higher compared to free doxorubicin, which indicate that Livatag nanoparticles have a preferential affinity for and are able to target the liver and more particularly, the liver tumor tissue.
As part of this program, Onxeo has also been exploring the potential of Livatag when administered with emerging immuno-oncology agents of various classes, such as promising PD-1 and CTLA-4 checkpoint inhibitors currently in development. A current study demonstrates that Livatag produces an enhanced effect in tumor response (reduction in tumor volume) when given in combination with immuno-oncology agents in the orthotopic HCC model. Specifically, Livatag co-administration with antibodies is associated with a positive increase in circulating T-cell populations, which is consistent with the observed reduction in tumor volume.
Graham Dixon, PhD, Chief Scientific Officer at Onxeo, said, "These preclinical findings are important because they reinforce our previous research showing that Livatag Transdrug technology dramatically improves the drug's exposure in liver cancer tissue, demonstrating high affinity for the liver, without increasing exposure in other organs. These data validate the interest of Livatag as a potential new therapeutic option for HCC treatment. Besides, we are pleased to share the first data demonstrating an enhanced anti-cancer response generated by Livatag in combination with immuno-oncology agents in murine HCC models. Results from this study will enable us to extend the value of one of our lead assets and add to the growing value of Onxeo's pipeline. In addition to sharing results from the Phase III ReLive trial next year, we look forward to continued evaluation of Livatag in combination with immunotherapy agents and delivering a plan to advance Livatag in the clinic in additional indications."
Onxeo is a developer of orphan oncology drugs.
((Comments on this story may be sent to email@example.com))
THE DAILY VIEW
Papyrus Joins Forces with Designer Lela Rose
Papyrus is looking to bring the “elegance and style” of fashion to its greeting cards via a new designer collaboration series.
According to a release, the collaboration marks the first time a fashion design house and greeting card brand have joined forces to develop a custom greeting card collection.
Papyrus said it is partnering with American fashion designer Lela Rose to introduce the series. Rose will feature her "sophisticated yet modern style" in the debut card and gift collection, slated to launch during New York Fashion Week. The collection will be available in New York City Papyrus stores and select retailers in September, with availability expanding to all Papyrus locations and retailers in October.
"The fashion designer collaboration series is a celebration of the commitment Papyrus has to the arts, including a focus on the fashion industry, quality craftsmanship and trend-forward design," said Christy Kaprosy, President of Papyrus-Recycled Greetings. "We are delighted to have Lela Rose's elegant line lead the first Papyrus fashion designer collaboration program, and we are excited to bring more fashion designers to our loyal customers in the future."
The company noted the collection, which draws inspiration from some of Rose's recent runway designs, consists of 16 cards and five gift accessories, including gift bags, gift tissue, roll wrap and a gift tag set. It also will be available online at papyrusonline.com
"I'm thrilled to be the first designer to collaborate with Papyrus on their exclusive new fashion series," said Lela Rose. "This is a unique way to showcase our designs, silhouettes and prints, and extend the brand into a new category."
- Big Gift: Bill Gates, founder and co-chair of the Bill & Melinda Gates Foundation, has committed $50 million to fight the epidemic.
- Early Donation: In August, Paul G. Allen Family Foundation donated $2.8 million toward the outbreak in West Africa.
- Latest Pledge: Facebook founder Mark Zuckerberg and his wife Priscilla Chan this month pledged $25 million to the CDC.
- Corporate Funds: World Bank Group in August pledged up to US $200 million in emergency funding to help Guinea, Liberia, and Sierra Leone contain the spread of infections.
- Crowdfunding: Scripps Research Institute's Erica Ollman Saphire seeks to raise $100K for equipment to speed her work, partially funding by U.S. government.